ScholarIQanswers from OpenAlex
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
InstitutionResearch output, impact & collaborations
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" is a institution indexed in ScholarIQ from OpenAlex.
What is known about Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"?
ScholarIQrecord summary
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" is a research organisation in Naples, IT. OpenAlex records 11,529 works and 1,129,531 citations for it. 2,105 researchers list it as their most recent affiliation.
How many works does Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" have?
ScholarIQindexed works
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" has 11,529 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" have?
ScholarIQcitation count
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" has 1,129,531 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"?
ScholarIQresearcher count
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" has 2,105 researchers in the ScholarIQ index.
What is the average h-index at Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"?
ScholarIQavg h-index
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" has an average h-index of 80.2 in OpenAlex.
What is the ROR of Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"?
ScholarIQror
The ROR for Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" is on the source record.
What is the OpenAlex record for Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"?
ScholarIQopenalex
The OpenAlex for Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" is on the source record.
Who are the most-cited researchers behind Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"?
ScholarIQtop researchers by citations
What are the most-cited papers on Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"?
ScholarIQmost cited works
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martı́n, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää, Frédèric Selle, Jalid Sehouli, Domenica Lorusso, Eva María Guerra Alia, Alexander Reinthaller, Shoji Nagao, Claudia Lefeuvre‐Plesse, Ulrich Canzler, Giovanni Scambia, Alain Lortholary, Frederik Marmé, Pierre Combe, Nikolaus de Gregorio, Manuel Rodrigues, Paul Buderath, Coraline Dubot, Alexander Burges, Benoît You, Éric Pujade-Lauraine, Philipp Harter
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Michele Maio, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Stefan Suciu, Caroline Robert
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Nicoletta Colombo, Cristiana Sessa, Andreas du Bois, Jonathan A. Ledermann, W. Glenn McCluggage, Iain A. McNeish, Philippe Morice, Sandro Pignata, Isabelle Ray‐Coquard, Ignace Vergote, Thaïs Baert, I. Belaroussi, A. Dashora, Siel Olbrecht, François Planchamp, Denis Querleu, Thaïs Baert, Susana Banerjee, I. Belaroussi, Paweł Blecharz, Ilan Bruchim, David Cibula, Nicoletta Colombo, Nicole Concin, Ben Davidson, A. Dashora, Mojgan Devouassoux‐Shisheboran, Andreas du Bois, Annamaria Ferrero, Rosalind Glasspool, Antonio González-Martı́n, Viola Heinzelmann‐Schwarz, Florence Joly, J.W. Kim, Frédéric Kridelka, Jonathan A. Ledermann, Domenica Lorusso, Sven� Mahner, W. Glenn McCluggage, Iain A. McNeish, Mikio Mikami, Mansoor Raza Mirza, Philippe Morice, Shibani Nicum, Siel Olbrecht, Dearbhaile M. O’Donnell, Patricia Pautier, François Planchamp, Sandro Pignata, Denis Querleu, Isabelle Ray‐Coquard, Alexandros Rodolakis, Jalid Sehouli, Fatih Selçukbırıcık, Cristiana Sessa, Nilanchali Singh, David S.P. Tan, D. Timmerman, Germana Tognon, Jacobus van der Velden, Ignace Vergote, Petronella O. Witteveen, Alain G. Zeimet
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, Jill Brufsky, Laura C. Cappelli, Frank B. Cortazar, David E. Gerber, Lamya Hamad, Eric Hansen, Douglas B. Johnson, Mario E. Lacouture, Gregory A. Masters, Jarushka Naidoo, Michele Nanni, Miguel‐Angel Perales, Igor Puzanov, Bianca Santomasso, Satish Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A. Sosman, Michelle Turner, Marc S. Ernstoff
How much of the research on Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" is open access?
ScholarIQopen access share
75%OPEN ACCESS